Q-omics provides the consensus-scored NUTM2F profile across patient tissues and cancer cell-line models. NUTM2F expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NUTM2F is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, NUTM2F protein abundance shows 18,949 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where NUTM2F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTM2F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTM2F survival associations across molecular data types. NUTM2F RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTM2F RNA expression–survival associations across cancer types. High NUTM2F expression shows unfavorable associations in ACC, PCPG, THCA, SARC and PRAD, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NUTM2F RNA expression.
This table summarizes NUTM2F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NUTM2F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTM2F shows lower tumor expression in KICH and LUAD and higher tumor expression in HNSC, BRCA, LUSC and PRAD. The HNSC box plot shows higher NUTM2F RNA expression in tumor versus normal tissue (log2 FC = +0.084, t-test p < 0.001).
This table shows molecular features associated with NUTM2F in patient tissues and cancer cell lines. In patient samples, NUTM2F shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NUTM2F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
